You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, T-Cell, Peripheral

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,

Recruiting
  • Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
  • Guangzhou, Guangdong, China
    Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Oct 7, 2022

T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)

Not yet recruiting
  • T Cell Lymphoma
  • New Haven, Connecticut
    Yale Smilow Cancer Hospital
Aug 14, 2023

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)

Enrolling by invitation
  • Peripheral T-cell Lymphoma Targeted Therapy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023

T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)

Not yet recruiting
  • T Cell Lymphoma
  • Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
  • (no location specified)
Mar 6, 2023

Previously Untreated Peripheral T-cell Lymphoma Trial in Tampa, Saint Louis, New York (CC-486 Administration, CHOP

Active, not recruiting
Has Results
  • Previously Untreated Peripheral T-cell Lymphoma
  • CC-486 Administration
  • CHOP Administration
  • Tampa, Florida
  • +3 more
Jan 18, 2023

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • (no location specified)
Jun 20, 2023

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

NK/T-cell Lymphoma Trial in Shanghai (Positron Emission Tomography/Magnetic Resonance (PET/MR))

Not yet recruiting
  • NK/T-cell Lymphoma
  • Positron Emission Tomography/Magnetic Resonance (PET/MR)
  • Shanghai, Shanghai, China
    Ruijin Hospital
Dec 14, 2022

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

Allo-HSCT as First-line Consolidation in High-risk PTCL

Recruiting
  • T Cell Lymphoma
    • Beijing, China
      Peking University People's Hospital
    Jul 31, 2022

    Peripheral T-cell Lymphoma Trial in Tianjin (Lposomal mitoxantrone HCl,Cyclophosphamide,Vincristine,Etoposide and

    Not yet recruiting
    • Peripheral T-cell Lymphoma
    • Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Insititute & Hospital
    Jul 13, 2022

    Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)

    Not yet recruiting
    • Cutaneous T Cell Lymphoma
    • Fungoides Mycosis Sezary Syndrome
    • Ann Arbor, Michigan
      University of Michigan Comprehensive Cancer Center
    Jul 13, 2023

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

    Active, not recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +10 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 30, 2023

    Peripheral T Cell Lymphoma Trial in Harlingen (Belinostat Injection, Pralatrexate Injection, CHOP)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • Belinostat Injection
    • +3 more
    • Harlingen, Texas
      Valley Cancer Associates
    Oct 16, 2023

    HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) Trial (Tipifarnib)

    Available
    • HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
    • (no location specified)
    Jun 7, 2022

    T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)

    Not yet recruiting
    • T-cell Lymphoma
    • +10 more
    • Chicago, Illinois
      Rush University Medical Center
    Oct 24, 2022

    Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

    Recruiting
    • Cutaneous T-Cell Lymphoma
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)

    Not yet recruiting
    • Relapsed or Refractory T-cell Lymphomas
    • Sendai-shi, Miyagi, Japan
      Local Institution - 0001
    Sep 12, 2023

    Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma Trial in Boston (Microdevices, Standard of care therapy, Standard of care

    Recruiting
    • Cutaneous T Cell Lymphoma
    • Peripheral T Cell Lymphoma
    • Microdevices
    • +2 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Jul 16, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    Peripheral T Cell Lymphoma Trial in Zhejiang (Mitoxantrone liposome?Chidamide?Azacitidine)

    Recruiting
    • Peripheral T Cell Lymphoma
    • Mitoxantrone liposome、Chidamide、Azacitidine
    • Zhejiang, Zhejiang, China
      Second Affiliated Hospital, School of Medicine, Zhejiang Univers
    Aug 9, 2022